

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL
EFFECTIVE DATE:	12/01/2003

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Pfizer Ireland Pharmaceuticals		12/01/2003	Unlimited Liability Company: IRELAND

RECEIVING PARTY DATA

Name:	Pfizer Ireland Pharmaceuticals
Composed Of:	COMPOSED OF C.P. Pharmaceuticals International C.V., a Netherlands limited partnership; Pfizer Production LLC, a Delaware limited liability company
Street Address:	Pottery Road, Dun Laoghaire Co.
City:	Dublin
State/Country:	IRELAND
Entity Type:	PARTNERSHIP: IRELAND

PROPERTY NUMBERS Total: 8

Property Type	Number	Word Mark
Registration Number:	2950116	ATORVASTATIN LANDMARK PROGRAM
Registration Number:	2973505	
Registration Number:	2950117	BUILDING INSIGHT THROUGH INVESTIGATION
Registration Number:	2896108	
Registration Number:	2992917	
Registration Number:	2891578	LIPITOR
Registration Number:	2992918	LIPITOR
Registration Number:	2726959	FLEXIBLE START

CORRESPONDENCE DATA

Fax Number: (212)573-2273
 Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

CH \$215.00 2950116

Phone: 212-733-4114
Email: barbara.batten@pfizer.com
Correspondent Name: Stacey Hallerman
Address Line 1: 150 East 42nd Street
Address Line 4: New York, NEW YORK 10017

DOMESTIC REPRESENTATIVE

Name: Stacey Hallerman
Address Line 1: 150 East 42nd Street
Address Line 4: New York, NEW YORK 10017

NAME OF SUBMITTER:	Stacey Hallerman
Signature:	/stacey hallerman/
Date:	12/20/2006

Total Attachments: 16

source=PIP Assignment_12-1-03#page1.tif
source=PIP Assignment_12-1-03#page2.tif
source=PIP Assignment_12-1-03#page3.tif
source=PIP Assignment_12-1-03#page4.tif
source=PIP Assignment_12-1-03#page6.tif
source=PIP Assignment_12-1-03#page8.tif
source=PIP Assignment_12-1-03#page10.tif
source=PIP Assignment_12-1-03#page12.tif
source=PIP Assignment_12-1-03#page13.tif
source=PIP Assignment_12-1-03#page14.tif
source=PIP Assignment_12-1-03#page16.tif
source=PIP Assignment_12-1-03#page18.tif
source=PIP Assignment_12-1-03#page20.tif
source=PIP Assignment_12-1-03#page22.tif
source=PIP Assignment_12-1-03#page23.tif
source=PIP Assignment_12-1-03#page25.tif

ASSIGNMENT

This Assignment is entered into, effective as of the 1st day of December, 2003, by and between,

I. **PFIZER IRELAND PHARMACEUTICALS** (in process of changing its name to Pfizer Overseas Pharmaceuticals), an unlimited liability company incorporated under the laws of Ireland, and having its registered office at Pottery Road, Dun Laoghaire, County Dublin, Republic of Ireland ("Assignor"); and

II. **PFIZER IRELAND PHARMACEUTICALS**, a partnership between (a) C.P. Pharmaceuticals International C.V., a limited partnership (*commanditaire vennootschap*) formed and established under the laws of the Netherlands and for all purposes duly represented by and acting for all purposes through its general partners Pfizer Manufacturing LLC, a limited liability company organised under the laws of the State of Delaware and having its office at 235 East 42nd Street, New York, New York 10017, USA and Pfizer Production LLC, a limited liability company organised under the laws of the State of Delaware and having its office at 235 East 42nd Street, New York, New York 10017, USA ("CPPI/CV") and (b) the Assignor (together, "Assignee").

RECITALS

I. **WHEREAS**, the Assignor is the owner of the trademarks listed on SCHEDULE A attached hereto and has made application for registration of the trademarks listed on SCHEDULE B attached hereto;

II. **WHEREAS**, the Assignor and the partners in CPPI/CV are all wholly owned members of the Pfizer group of companies; and

III. **WHEREAS**, the Assignor wishes to transfer to the Assignee, and the Assignee wishes to acquire (i) ownership of the trademark registrations listed on SCHEDULE A and (ii) the benefit of the trademark applications listed on SCHEDULE B.

NOW, THEREFORE, for valuable consideration, the receipt and sufficiency of which is hereby acknowledged by the Assignor and the Assignee, the Assignor and the Assignee agree as follows:-

I. **Definition.** In this Assignment, the term TRADEMARK PROPERTIES means (i) the trademarks listed on SCHEDULE A and (ii) the benefit of the trademark applications listed on SCHEDULE B and all of the goodwill associated with such trademarks and trademark applications.

II. **Assignment.** The Assignor hereby assigns, sells, transfers and delivers to the Assignee, its successors, legal representatives and assigns, free of all encumbrances, all of the Assignor's rights, title and interest in and to the TRADEMARK PROPERTIES, in all countries of the world, including all statutory

and common law rights attaching thereto, all rights therein provided under international conventions and treaties, and all rights to sue for damages and all other remedies in respect of any past, present or future infringement or other adverse actions, and to retain any and all proceeds therefrom. With respect to the trademark applications which form a part of the TRADEMARK PROPERTIES, it is the intent of the Assignor and the Assignee that any trademarks maturing therefrom and any and all goodwill associated therewith shall be in the name of, and ownership shall vest in, the Assignee.

III. **Cooperation.** The Assignor and the Assignee shall cooperate at all times, from and after the effective date of this Assignment, at the reasonable discretion and expense of the Assignee, to execute any and all documents, and perform any and all other acts, which may reasonably be required, to give effect to this Assignment, and in particular to perfect the Assignee's right, title and ownership interest in the TRADEMARK PROPERTIES, and to record or register the Assignee's right, title and ownership interest in the TRADEMARK PROPERTIES in the various intellectual property offices around the world.

IV. **Binding Effect.** This Assignment shall be binding on and inure to the benefit of the Assignor and the Assignee, and the legal and personal representatives, successors and assigns of the Assignor and the Assignee.

V. **Applicable Law.** This Assignment shall be governed by the laws of the State of New York, United States of America, but without applying the choice of law rules of said State of New York; and Assignor and Assignee hereby agree to submit to the exclusive jurisdiction of the courts of said State of New York for the resolution of any disputes arising hereunder.

VI. **Amendments.** No amendment, alteration, modification or waiver of this Assignment, nor any part thereof, shall be valid or effective, unless in writing and signed by both the Assignor and the Assignee.

IN WITNESS WHEREOF, and intending to be bound, the Assignor and the Assignee have caused this Assignment to be executed.

SCHEDULE A
(Trademarks)

REDACTED

REDACTED

REDACTED

REDACTED

REDACTED

United States

FLEXIBLE START

2726959

SCHEDULE B
(Trademark Applications)

REDACTED

REDACTIA

REDACTED

REDACTED

REDACTED

REDACTED

United States	ATORVASTATIN LANDMARK PROGRAM	78/271918
United States	ATORVASTATIN LANDMARK PROGRAM LOGO	
United States	BUILDING INSIGHT THROUGH INVESTIGATION	78/271921

United States	LIPITOR & DESIGN (CIRCLES)	76/338379
United States	LIPITOR & DESIGN (CIRCLES)	UNKNOWN
United States	LIPITOR DESIGN (CIRCLES)	76/338380
United States	LIPITOR DESIGN (CIRCLES)	76/554275

REDACTED

ON BEHALF OF ASSIGNOR

PRESENT when the common seal of
PFIZER IRELAND PHARMACEUTICALS
was affixed hereto

)
) *Peter Dwyer*
) *CLG*

ON BEHALF OF ASSIGNEE

C.P. PHARMACEUTICALS INTERNATIONAL C.V
duly represented by and acting through its general partners

Pfizer Production LLC, in the capacity of general partner for and on behalf
of C.P. Pharmaceuticals International C.V.

Marguerite Sells

By: MARGUERITE SELLS
Title: ATTORNEY-IN-FACT

Pfizer Manufacturing LLC, in the capacity of general partner for and on behalf
of C.P. Pharmaceuticals International C.V.

David Reid

By: DAVID REID
Title: Manager

PRESENT when the common seal of
PFIZER IRELAND PHARMACEUTICALS
was affixed hereto

)
) *Peter Dwyer*
) *CLG*